FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807708506> ?p ?o ?g. }

• W2807708506 endingPage "1498" @default.
• W2807708506 startingPage "1489" @default.
• W2807708506 abstract "Objective To evaluate the safety, tolerability and efficacy of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE) beyond 1 year. Methods This was a 24-week, open-label extension following a 52-week, double-blind, placebo-controlled trial of belimumab SC. Patients who completed the double-blind phase were eligible to enter the open-label phase. All patients received weekly belimumab 200 mg SC plus standard SLE therapy. Outcome measures included safety and efficacy (SLE Response Index (SRI) and SLE Flare Index (SFI) rates), and changes in biomarker and B cell levels. Results Of 677 patients who completed the 52-week, double-blind phase, 662 entered the open-label phase; 206 had previously received placebo and 456 had previously received belimumab. Despite differences in total belimumab exposure (24 weeks in the placebo-to-belimumab group versus 76 weeks in the belimumab group), the proportions of patients experiencing more than one adverse event (AE) or a serious AE in the open-label phase were similar between groups (placebo-to-belimumab: 51.5 and 6.8%; belimumab: 48.2 and 5.5%, respectively). Most AEs were mild/moderate in severity. Efficacy was maintained through the extension phase. An SRI response was achieved by 16.1% of patients in the placebo-to-belimumab group and 76.3% patients in the belimumab group. Furthermore, 1.0% of patients in the placebo-to-belimumab group and 2.6% of patients in the belimumab group experienced a severe SFI flare. Conclusion Belimumab SC was well tolerated and efficacy was maintained during the extension phase of this study. The safety profile of belimumab SC is consistent with that of previous experience with belimumab. Trial registration ClinicalTrials.gov identifier: NCT01484496" @default.
• W2807708506 created "2018-06-13" @default.
• W2807708506 creator A5019245481 @default.
• W2807708506 creator A5023033500 @default.
• W2807708506 creator A5026822726 @default.
• W2807708506 creator A5029641944 @default.
• W2807708506 creator A5034488510 @default.
• W2807708506 creator A5047601269 @default.
• W2807708506 creator A5050678710 @default.
• W2807708506 creator A5051145762 @default.
• W2807708506 creator A5072719649 @default.
• W2807708506 creator A5079808611 @default.
• W2807708506 creator A5086018261 @default.
• W2807708506 date "2018-05-28" @default.
• W2807708506 modified "2023-10-16" @default.
• W2807708506 title "A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus" @default.
• W2807708506 cites W1523486205 @default.
• W2807708506 cites W1718641735 @default.
• W2807708506 cites W2032689439 @default.
• W2807708506 cites W2060208115 @default.
• W2807708506 cites W2070527591 @default.
• W2807708506 cites W2081559577 @default.
• W2807708506 cites W2091468965 @default.
• W2807708506 cites W2115092402 @default.
• W2807708506 cites W2131457901 @default.
• W2807708506 cites W2136149088 @default.
• W2807708506 cites W2148749566 @default.
• W2807708506 cites W2255119417 @default.
• W2807708506 cites W2327267263 @default.
• W2807708506 cites W2339735591 @default.
• W2807708506 cites W2549420521 @default.
• W2807708506 cites W2610724709 @default.
• W2807708506 cites W2775607224 @default.
• W2807708506 doi "https://doi.org/10.1177/0961203318777634" @default.
• W2807708506 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6066857" @default.
• W2807708506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29807477" @default.
• W2807708506 hasPublicationYear "2018" @default.
• W2807708506 type Work @default.
• W2807708506 sameAs 2807708506 @default.
• W2807708506 citedByCount "22" @default.
• W2807708506 countsByYear W28077085062018 @default.
• W2807708506 countsByYear W28077085062019 @default.
• W2807708506 countsByYear W28077085062020 @default.
• W2807708506 countsByYear W28077085062021 @default.
• W2807708506 countsByYear W28077085062022 @default.
• W2807708506 countsByYear W28077085062023 @default.
• W2807708506 crossrefType "journal-article" @default.
• W2807708506 hasAuthorship W2807708506A5019245481 @default.
• W2807708506 hasAuthorship W2807708506A5023033500 @default.
• W2807708506 hasAuthorship W2807708506A5026822726 @default.
• W2807708506 hasAuthorship W2807708506A5029641944 @default.
• W2807708506 hasAuthorship W2807708506A5034488510 @default.
• W2807708506 hasAuthorship W2807708506A5047601269 @default.
• W2807708506 hasAuthorship W2807708506A5050678710 @default.
• W2807708506 hasAuthorship W2807708506A5051145762 @default.
• W2807708506 hasAuthorship W2807708506A5072719649 @default.
• W2807708506 hasAuthorship W2807708506A5079808611 @default.
• W2807708506 hasAuthorship W2807708506A5086018261 @default.
• W2807708506 hasBestOaLocation W28077085061 @default.
• W2807708506 hasConcept C126322002 @default.
• W2807708506 hasConcept C142724271 @default.
• W2807708506 hasConcept C159654299 @default.
• W2807708506 hasConcept C170286685 @default.
• W2807708506 hasConcept C197934379 @default.
• W2807708506 hasConcept C203014093 @default.
• W2807708506 hasConcept C204787440 @default.
• W2807708506 hasConcept C27081682 @default.
• W2807708506 hasConcept C2778375690 @default.
• W2807708506 hasConcept C2778453870 @default.
• W2807708506 hasConcept C2781205201 @default.
• W2807708506 hasConcept C535046627 @default.
• W2807708506 hasConcept C71924100 @default.
• W2807708506 hasConceptScore W2807708506C126322002 @default.
• W2807708506 hasConceptScore W2807708506C142724271 @default.
• W2807708506 hasConceptScore W2807708506C159654299 @default.
• W2807708506 hasConceptScore W2807708506C170286685 @default.
• W2807708506 hasConceptScore W2807708506C197934379 @default.
• W2807708506 hasConceptScore W2807708506C203014093 @default.
• W2807708506 hasConceptScore W2807708506C204787440 @default.
• W2807708506 hasConceptScore W2807708506C27081682 @default.
• W2807708506 hasConceptScore W2807708506C2778375690 @default.
• W2807708506 hasConceptScore W2807708506C2778453870 @default.
• W2807708506 hasConceptScore W2807708506C2781205201 @default.
• W2807708506 hasConceptScore W2807708506C535046627 @default.
• W2807708506 hasConceptScore W2807708506C71924100 @default.
• W2807708506 hasIssue "9" @default.
• W2807708506 hasLocation W28077085061 @default.
• W2807708506 hasLocation W28077085062 @default.
• W2807708506 hasLocation W28077085063 @default.
• W2807708506 hasLocation W28077085064 @default.
• W2807708506 hasOpenAccess W2807708506 @default.
• W2807708506 hasPrimaryLocation W28077085061 @default.
• W2807708506 hasRelatedWork W1966047811 @default.
• W2807708506 hasRelatedWork W2003042623 @default.
• W2807708506 hasRelatedWork W202460821 @default.
• W2807708506 hasRelatedWork W2030348591 @default.
• W2807708506 hasRelatedWork W2068849886 @default.
• W2807708506 hasRelatedWork W2085830368 @default.

• next